Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin

Advances in the biology of malignant pleural mesothelioma

(2011) P.A. Zucali et al.   CANCER TREATMENT REVIEWS

Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin

(2011) P. A. Zucali et al.   CLINICAL CANCER RESEARCH

Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial

(2011) Richard H. de Boer et al.   JOURNAL OF CLINICAL ONCOLOGY

The role of folate receptor alpha (FRα) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy

(2010) J E Nutt et al.   BRITISH JOURNAL OF CANCER

Thymidylate Synthase But Not Excision Repair Cross-Complementation Group 1 Tumor Expression Predicts Outcome in Patients With Malignant Pleural Mesothelioma Treated With Pemetrexed-Based Chemotherapy

(2010) Luisella Righi et al.   JOURNAL OF CLINICAL ONCOLOGY

Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma

(2010) Rabab Gaafar et al.   LUNG CANCER

Synergistic effect of gefitinib and rofecoxib in mesothelioma cells

(2010) Daniela Stoppoloni et al.   Molecular Cancer

Association of Polymorphisms in AKT1 and EGFR with Clinical Outcome and Toxicity in Non-Small Cell Lung Cancer Patients Treated with Gefitinib

(2010) E. Giovannetti et al.   MOLECULAR CANCER THERAPEUTICS

Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines

(2009) Sara Nannizzi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Growth inhibition by tyrosine kinase inhibitors in mesothelioma cell lines

(2009) Joyce E. Nutt et al.   EUROPEAN JOURNAL OF CANCER

Distinct Patterns of Cytokine and Angiogenic Factor Modulation and Markers of Benefit for Vandetanib and/or Chemotherapy in Patients With Non–Small-Cell Lung Cancer

(2009) Emer O. Hanrahan et al.   JOURNAL OF CLINICAL ONCOLOGY

Next generation oncology drug development: opportunities and challenges

(2009) Martin E. Gutierrez et al.   Nature Reviews Clinical Oncology

Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation

(2008) D Balin-Gauthier et al.   BRITISH JOURNAL OF CANCER

Molecular pathways involved in the synergistic interaction of the PKCβ inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells

(2008) C Tekle et al.   BRITISH JOURNAL OF CANCER

Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement

(2008) Hirokazu Ogino et al.   CANCER LETTERS

Epidermal Growth Factor Receptor Controls Flat Dysplastic Aberrant Crypt Foci Development and Colon Cancer Progression in the Rat Azoxymethane Model

(2008) U. Dougherty et al.   CLINICAL CANCER RESEARCH

Systemic Treatments for Mesothelioma: Standard and Novel

(2008) Hedy Lee Kindler   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

(2008) John V. Heymach et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Mechanisms Underlying the Synergistic Interaction of Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, with the Multitargeted Antifolate Pemetrexed in Non-Small-Cell Lung Cancer Cells

(2008) E. Giovannetti et al.   MOLECULAR PHARMACOLOGY